Literature DB >> 34543590

Community-based Lung Cancer Screening Results in Relation to Patient and Radiologist Characteristics: The PROSPR Consortium.

Andrea N Burnett-Hartman1, Nikki M Carroll1, Stacey A Honda2, Caroline Joyce1, Nandita Mitra3, Christine Neslund-Dudas4, Oluwatosin Olaiya5, Katharine A Rendle3, Mitchell D Schnall3, Anil Vachani3, Debra P Ritzwoller1.   

Abstract

Rationale: Lung-RADS classification was developed to standardize reporting and management of lung cancer screening using low-dose computed tomographic (LDCT) imaging. Although variation in Lung-RADS distribution between healthcare systems has been reported, it is unclear if this is explained by patient characteristics, radiologist experience with lung cancer screening, or other factors.
Objectives: Our objective was to determine if patient or radiologist factors are associated with Lung-RADS score.
Methods: In the Population-based Research to Optimize the Screening Process (PROSPR) Lung consortium, we conducted a study of patients who received their first screening LDCT imaging at one of the five healthcare systems in the PROSPR Lung Research Center from May 1, 2014, through December 31, 2017. Data on LDCT scans, patient factors, and radiologist characteristics were obtained via electronic health records. LDCT scan findings were categorized using Lung-RADS (negative [1], benign [2], probably benign [3], or suspicious [4]). We used generalized estimating equations with a multinomial distribution to compare the odds of Lung-RADS 3, and separately Lung-RADS 4, versus Lung-RADS 1 or 2 and estimated adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between Lung-RADS assignment and patient and radiologist characteristics.
Results: Analyses included 8,556 patients; 24% were assigned Lung-RADS 1, 60% Lung-RADS 2, 10% Lung-RADS 3, and 5% Lung-RADS 4. Age was positively associated with Lung-RADS 3 (OR, 1.02; 95% CI, 1.01-1.03) and 4 (OR, 1.03; 95% CI, 1.01-1.05); chronic obstructive pulmonary disease (COPD) was positively associated with Lung-RADS 4 (OR, 1.78; 95% CI, 1.45-2.20); obesity was inversely associated with Lung-RADS 3 (OR, 0.70; 95% CI, 0.58-0.84) and 4 (OR, 0.58; 95% CI, 0.45-0.75). There was no association between sex, race, ethnicity, education, or smoking status and Lung-RADS assignment. Radiologist volume of interpreting screening LDCT scans, years in practice, and thoracic specialty were also not associated with Lung-RADS assignment. Conclusions: Healthcare systems that are comprised of patients with an older age distribution or higher levels of COPD will have a greater proportion of screening LDCT scans with Lung-RADS 3 or 4 findings and should plan for additional resources to support appropriate and timely management of noted positive findings.

Entities:  

Keywords:  LDCT; Lung-RADS; lung cancer screening; radiologist

Mesh:

Year:  2022        PMID: 34543590      PMCID: PMC8937226          DOI: 10.1513/AnnalsATS.202011-1413OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  39 in total

1.  Evaluating Lung Cancer Screening Across Diverse Healthcare Systems: A Process Model from the Lung PROSPR Consortium.

Authors:  Chyke A Doubeni; Debra P Ritzwoller; Katharine A Rendle; Andrea N Burnett-Hartman; Christine Neslund-Dudas; Robert T Greenlee; Stacey Honda; Jennifer Elston Lafata; Pamela M Marcus; Mary E Cooley; Anil Vachani; Rafael Meza; Caryn Oshiro; Michael J Simoff; Mitchell D Schnall; Elisabeth F Beaber; V Paul Doria-Rose
Journal:  Cancer Prev Res (Phila)       Date:  2019-12-23

Review 2.  Screening for lung cancer: A systematic review and meta-analysis.

Authors:  Muhammad Usman Ali; John Miller; Leslea Peirson; Donna Fitzpatrick-Lewis; Meghan Kenny; Diana Sherifali; Parminder Raina
Journal:  Prev Med       Date:  2016-04-26       Impact factor: 4.018

3.  Results of the two incidence screenings in the National Lung Screening Trial.

Authors:  Denise R Aberle; Sarah DeMello; Christine D Berg; William C Black; Brenda Brewer; Timothy R Church; Kathy L Clingan; Fenghai Duan; Richard M Fagerstrom; Ilana F Gareen; Constantine A Gatsonis; David S Gierada; Amanda Jain; Gordon C Jones; Irene Mahon; Pamela M Marcus; Joshua M Rathmell; JoRean Sicks
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

4.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

5.  Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.

Authors:  Harry J de Koning; Carlijn M van der Aalst; Pim A de Jong; Ernst T Scholten; Kristiaan Nackaerts; Marjolein A Heuvelmans; Jan-Willem J Lammers; Carla Weenink; Uraujh Yousaf-Khan; Nanda Horeweg; Susan van 't Westeinde; Mathias Prokop; Willem P Mali; Firdaus A A Mohamed Hoesein; Peter M A van Ooijen; Joachim G J V Aerts; Michael A den Bakker; Erik Thunnissen; Johny Verschakelen; Rozemarijn Vliegenthart; Joan E Walter; Kevin Ten Haaf; Harry J M Groen; Matthijs Oudkerk
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 91.245

6.  Overdiagnosis in low-dose computed tomography screening for lung cancer.

Authors:  Edward F Patz; Paul Pinsky; Constantine Gatsonis; Jorean D Sicks; Barnett S Kramer; Martin C Tammemägi; Caroline Chiles; William C Black; Denise R Aberle
Journal:  JAMA Intern Med       Date:  2014-02-01       Impact factor: 21.873

7.  Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.

Authors:  Peter J Mazzone; Gerard A Silvestri; Sheena Patel; Jeffrey P Kanne; Linda S Kinsinger; Renda Soylemez Wiener; Guy Soo Hoo; Frank C Detterbeck
Journal:  Chest       Date:  2018-02-17       Impact factor: 9.410

Review 8.  American Cancer Society lung cancer screening guidelines.

Authors:  Richard Wender; Elizabeth T H Fontham; Ermilo Barrera; Graham A Colditz; Timothy R Church; David S Ettinger; Ruth Etzioni; Christopher R Flowers; G Scott Gazelle; Douglas K Kelsey; Samuel J LaMonte; James S Michaelson; Kevin C Oeffinger; Ya-Chen Tina Shih; Daniel C Sullivan; William Travis; Louise Walter; Andrew M D Wolf; Otis W Brawley; Robert A Smith
Journal:  CA Cancer J Clin       Date:  2013-01-11       Impact factor: 508.702

9.  Real-world Clinical Implementation of Lung Cancer Screening-Evaluating Processes to Improve Screening Guidelines-Concordance.

Authors:  Nikki M Carroll; Andrea N Burnett-Hartman; Caroline A Joyce; William Kinnard; Eric J Harker; Virginia Hall; Julie S Steiner; Erica Blum-Barnett; Debra P Ritzwoller
Journal:  J Gen Intern Med       Date:  2020-01-23       Impact factor: 5.128

10.  Overall and Central Obesity and Risk of Lung Cancer: A Pooled Analysis.

Authors:  Danxia Yu; Wei Zheng; Mattias Johansson; Qing Lan; Yikyung Park; Emily White; Charles E Matthews; Norie Sawada; Yu-Tang Gao; Kim Robien; Rashmi Sinha; Arnulf Langhammer; Rudolf Kaaks; Edward L Giovannucci; Linda M Liao; Yong-Bing Xiang; DeAnn Lazovich; Ulrike Peters; Xuehong Zhang; Bas Bueno-de-Mesquita; Walter C Willett; Shoichiro Tsugane; Yumie Takata; Stephanie A Smith-Warner; William Blot; Xiao-Ou Shu
Journal:  J Natl Cancer Inst       Date:  2018-08-01       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.